Ardian sells Groupe Bio7 to trade

Founded in 1967, Cerba is a French pharmaceutical group active in the field of clinical pathology. The group has been owned since January 2017 by Partners Group and Canadian pension fund PSP Investments. Cerba was previously owned by PAI Partners.

Ardian acquired a minority stake in the Bio7 group from Chequers Capital in June 2014. At the time of the buyout, Bio7 expected net revenues in excess of €55m. Chequers first acquired a stake in the group alongside the founders and the management team in 2009.

Company
Founded in 1991, Bio7 is a clinical pathology group headquartered in Lisses. With around 70 laboratories, the group has a strong presence in the Île-de-France region. Since 2016, Bio7 has extended its presence across the rest of France, notably in the Indre-et-Loire and Oise regions.

Bio7 has a workforce of around 500 and is expected to generate pro forma revenue in excess of €110m in 2018.

People
Groupe Bio7 – Frédéric Barroux (chair).
Ardian – François Jerphagnon (head of Ardian expansion).
Cerba HealthCare – Catherine Courboillet (CEO).
Partners Group – Christoph Rubeli (partner).
PSP Investments – Simon Marc (managing director, head of private equity).

Advisers
Company – Goodwin Procter, Maxence Bloch, William Robert (legal).
Equity, management – Latham & Watkins, Olivier du Mottay, Louis Paumier, Marion Lebastard (legal); Hottinguer Corporate Finance, Pierre de Bousingen, Djilali Bou-abdallah, Arthur Gautier (M&A).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• France
• Healthcare
• Portfolio management
• France
• Ardian (formerly Axa PE)
• Partners Group
• Build-up
• Trade sale